Avatar
Seeking Alpha @seekingalpha.com · 2 d

#HealthcareInnovation #Biopharmaceuticals #GlobalMarkets

Link Preview
seekingalpha.com
Hello, Goodbye: Europe Loses Ground As China Becomes Powerhouse Of Innovation
However, in recent years, China has surpassed Europe in the number of new global drug approvals, and it is edging closer to the US.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Biopharmaceuticals #Neuroscience #HealthcareInnovation

Link Preview
www.benzinga.com
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Xenon Pharmaceuticals (NASDAQ:XENE)
VANCOUVER, British Columbia and BOSTON, Jan.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#GeneticMedicine #Biopharmaceuticals #Leadership

Link Preview
www.benzinga.com
ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors
WALTHAM, Mass.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Pelthos #Xeglyze #Biopharmaceuticals

Link Preview
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Biopharmaceuticals #GeneticDiseases #HealthcareConference

Link Preview
www.benzinga.com
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - BridgeBio Pharma (NASDAQ:BBIO)
PALO ALTO, Calif.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Biopharmaceuticals #LiverDisease #FDAApproval

Link Preview
www.benzinga.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Altimmune (NASDAQ:ALT)
GAITHERSBURG, Md.
Avatar
NASDAQ Stock Market @nasdaq.com · New York City 🇺🇸· 2 t

#biopharmaceuticals #cancerresearch #clinicaltrials

Link Preview
www.nasdaq.com
HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer
(RTTNews) - HUTCHMED (China) Ltd (HCM, HCM.